SCHEMBL3695612

SCHEMBL3695612

CC(C)(C)OC(=O)NC(C)(CNC(C)(C)C(=O)O)c1cc(F)cc(F)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.34
CTSK P43235 3/20 0.34
AAK1 Q2M2I8 4/20 0.34
SLC6A3 Q01959 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MRGPRX4 Q96LA9 1/20 0.31
APLNR P35414 1/20 0.31
ACE P12821 1/20 0.31
MAPT P10636 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA7 P43166 1/20 0.30
CA14 Q9ULX7 1/20 0.30
PPARG P37231 1/20 0.30
PPARA Q07869 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
MKNK2 Q9HBH9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980274 0.76 CTSS (0.39) CTSSCTSKAAK1SLC6A3KDM4E
SCHEMBL977548 0.76 AAK1 (0.31) AAK1
SCHEMBL977549 0.76 AAK1 (0.31) AAK1
SCHEMBL17040319 0.74 APLNR (0.38) CTSSCTSKAAK1SLC6A3KDM4E
SCHEMBL3706008 0.74 SLC6A3 (0.33) SLC6A3MAPT
SCHEMBL979457 0.73 BACE1 (0.33) AAK1
SCHEMBL977080 0.72 BACE1 (0.35) AAK1
SCHEMBL978932 0.72 AAK1 (0.32) AAK1SLC6A3
SCHEMBL978931 0.72 AAK1 (0.32) AAK1SLC6A3
SCHEMBL6343801 0.71 AAK1 (0.36) CTSSCTSKAAK1SLC6A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507477-B2 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme, Corp. (US) 2013-08-13 US disclosed
US-8507477-B2 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme, Corp. (US) 2013-08-13 US disclosed
US-20120121508-A1 RADIOLABELED CGRP ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2012-05-17 US disclosed
US-20110306604-A1 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-12-15 US disclosed
US-20110306604-A1 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121508-A1 RADIOLABELED CGRP ANTAGONISTS CALCRL, CALCR, GRPR CTSS 1391/4885CTSK 1067/4885AAK1 3577/4885
US-20110306604-A1 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS CALCRL, CCKBR, CCKAR CTSS 991/4885CTSK 970/4885AAK1 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.